Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 132

Sort by

Sort Order Select

Journal Articles

Single Cell Transcriptomic Analysis of B-Cell Acute Lymphoblastic Leukemia (B-ALL) Reveals Correlation between Leukemia Cell State, Genetic Alterations and Clinical Outcome

Ilaria Iacobucci, Andy G.X. Zeng, Qingsong Gao, Laura Garcia Prat, Pradyumna Baviskar, Sayyam Shah, Alexander Murison, Veronique Voisin, Colin Bailey, Matthew Lear, Anjali S. Advani, Selina M Luger, Elisabeth Paietta, Wendy Stock, John E. Dick, Charles G. Mullighan

Blood (2023) 142 (Supplement 1): 841.

https://doi.org/10.1182/blood-2023-190180

Published: 2023

Journal Articles

The Impact of Age and Genomics on Drug Sensitivity in 1,076 Children and Adults with B-Cell Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 596.

https://doi.org/10.1182/blood-2023-181788

Published: 2023

Journal Articles

STAG2/LMO2 Gamma-Delta (γδ) T-ALL: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young

Shunsuke Kimura, Petri Pölönen, Lindsey Montefiori, Kenneth Caldwell, Ilaria Iacobucci, Chelsey Chen, Anthony Brown, Katie Han, Yen-Chun Liu, Yunchao Chang, Zhongshan Cheng, Zhou Yinmei, Chun Shik Park, Sharnise Mitchell, Noemi Reyes, Allen Yeoh, Andishe Attarbaschi, Andrew Moore, Atsushi Manabe, Barbara Buldini, Kean Hui Chiew, Chi Kong Li, Ching-Hon Pui, Chunxu Qu, Daisuke Tomizawa, Elisabeth Paietta, Franco Locatelli, Gabriele Escherich, Gao Qingsong, Hannah Elisa Muhle, Hanne Vibeke Marquart, Hester A. de Groot-Kruseman, Jacob M. Rowe, Jan Stary, Jan Trka, John Kim Choi, Jules P.P. Meijerink, Junko Takita, Katarzyna Pawinska-Wasikowska, Kjeld Schmiegelow, Mariko Eguchi, Martin Schrappe, Martin Zimmermann, Masatoshi Takagi, Melissa Maybury, Michael Svaton, Michaela Reiterova, Michal Kicinski, Motohiro Kato, Orietta Spinelli, Pauline Mazilier, Paul G. Thomas, Riccardo Masetti, Rishi Sury Kotecha, Rob Pieters, Sarah Elitzur, Selina M Luger, Shuhong Shen, Sima Jeha, Steven M. Kornblau, Szymon Skoczen, Takako Miyamura, Tiffaney Vincent, Toshihiko Imamura, Valentino Conter, Yanjing Tang, Zhaohui Gu, Kathryn G. Roberts, David T. Teachey, Kristine R Crews, Cheng Cheng, Jun J. Yang, Hiroto Inaba, Charles G. Mullighan

Blood (2023) 142 (Supplement 1): 845.

https://doi.org/10.1182/blood-2023-178688

Published: 2023

Journal Articles

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Blood (2023) 142 (Supplement 1): 2877.

https://doi.org/10.1182/blood-2023-189648

Published: 2023

Journal Articles

Dynamic Recruitment of Inhibitory Complexes Controls Oncogenic Signaling in B-Cell Malignancies

Ruifeng Sun, Jaewoong Lee, Mark E Robinson, Kohei Kume, Ning Ma, Kadriye Nehir Cosgun, Lai N Chan, Irina Antoshkina, Dhruv Khanduja, Etienne Leveille, Samuel G. Katz, Jianjun Chen, Elisabeth Paietta, Nagarajan Vaidehi, Markus Müschen

Blood (2023) 142 (Supplement 1): 719.

https://doi.org/10.1182/blood-2023-189742

Published: 2023

Journal Articles

A Pro-Inflammatory Gene Signature Characterizes a Better Risk Aged AML Patient Group in ECOG-ACRIN Cancer Research Group's Clinical Trial E3999

Blood (2023) 142 (Supplement 1): 4326.

https://doi.org/10.1182/blood-2023-179569

Published: 2023

Journal Articles

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Blood (2022) 140 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2022-171751

Published: 2022

Journal Articles

DNA Polymerase Theta Protects Leukemia Cells from Metabolic-Induced DNA Damage

Blood (2022) 140 (Supplement 1): 2972–2974.

https://doi.org/10.1182/blood-2022-156458

Published: 2022

Journal Articles

Epigenetic Fine Mapping and Functional Dissection of Inherited Non-Coding Variation Impacting the Pharmacogenomics of Acute Lymphoblastic Leukemia Treatment

Kashi Raj Bhattarai, Kelly R. Barnett, Robert J. Mobley, Daniel C. Ferguson, Jonathan D. Diedrich, Brennan P. Bergeron, Wenjian Yang, Kristine R. Crews, Wendy Stock, Elisabeth Paietta, Steven M. Kornblau, Hiroto Inaba, Sima Jeha, Ching-Hon Pui, Cheng Cheng, Mary V. Relling, William E. Evans, Jun J.J. Yang, Daniel Savic

Blood (2022) 140 (Supplement 1): 3027–3028.

https://doi.org/10.1182/blood-2022-167419

Published: 2022

Journal Articles

PAX5 Epigenetically Orchestrates CD58 Transcription and Modulates Blinatumomab Response in Acute Lymphoblastic Leukemia

Yizhen Li, Takaya Moriyama, Satoshi Yoshimura, Xuijie Zhao, Zhenhua LI, Xu Yang, Jacob A Steele, Shondra Miller, Elisabeth Paietta, Marina Konopleva, Jiyang Yu, Hiroto Inaba, Raul C Ribeiro, Ching-Hon Pui, Jun J. Yang

Blood (2022) 140 (Supplement 1): 1041–1042.

https://doi.org/10.1182/blood-2022-156746

Published: 2022

Journal Articles

Chromatin Accessibility Landscapes of B-Cell Acute Lymphoblastic Leukemia Identify Extensive Epigenomic Reprogramming and Heterogeneity Among Subtypes

Kelly R. Barnett, Jonathan D. Diedrich, Brennan P. Bergeron, Wenjian Yang, Kristine R. Crews, Wendy Stock, Elisabeth Paietta, Steven M. Kornblau, Hiroto Inaba, Sima Jeha, Ching-Hon Pui, Mary V. Relling, William E. Evans, Jun J.J. Yang, Daniel Savic

Blood (2022) 140 (Supplement 1): 5907–5908.

https://doi.org/10.1182/blood-2022-166528

Published: 2022

Journal Articles

Characteristics and Prognostic Effects of DNMT3A Co-Mutations

Blood (2022) 140 (Supplement 1): 745–747.

https://doi.org/10.1182/blood-2022-162526

Published: 2022

Journal Articles

A Phosphatase Membrane-Shuttle Enables Feedback Control of B-Cell Signaling

Blood (2022) 140 (Supplement 1): 1698–1699.

https://doi.org/10.1182/blood-2022-170324

Published: 2022

Journal Articles

Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152

Neil Palmisiano, Ju-Whei Lee, David F. Claxton, Elisabeth Paietta, Hassan B. Alkhateeb, Jae H Park, Nikolai Podoltsev, Ehab L. Atallah, Dale G Schaar, Shira Dinner, Jonathan Webster, Selina M. Luger, Mark R. Litzow

Blood (2021) 138 (Supplement 1): 3407.

https://doi.org/10.1182/blood-2021-153621

Published: 2021

Journal Articles

Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study

Yishai Ofran, Zhuoxin Sun, Jacob M. Rowe, David F. Claxton, Martin S. Tallman, Daniel A. Arber, Ari Melnick, Ross L. Levine, Elisabeth Paietta, John E. Godwin, Hillard M Lazarus, Selina M. Luger, James M. Foran, Mark R. Litzow

Blood (2021) 138 (Supplement 1): 413.

https://doi.org/10.1182/blood-2021-149356

Published: 2021

Journal Articles

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL

Blood (2021) 138 (11): 948–958.

https://doi.org/10.1182/blood.2020010144

Published: 2021

Includes: Supplemental data

Journal Articles

Early Assessment of Treatment Response in Acute Myeloid Leukemia Using FLT PET/CT Imaging: A Trial of the ECOG-ACRIN Cancer Research Group (EAI141)

Robert Jeraj, PhD, Fenghai Duan, PhD, Ryan J. Mattison, MD, Lale Kostakoglu, MD MPH, Daniel A. Arber, MD, Elisabeth Paietta, PhD, Justin Romanoff, AM, Jennifer Holter-Chakrabarty, MD, Charles Arnold, MD, Stephen A. Strickland, MD, Jennifer Whisenant, PhD, Barry Alan Siegel, MD, Geoffrey L Uy, MD, Kebede H. Begna, MD, Gregory Wiseman, MD, Aric C. Hall, MD, Scott Perlman, MD, Mark Litzow, MD, David Mankoff, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136721

Published: 2020

Journal Articles

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

Blood (2019) 134 (Supplement_1): 115.

https://doi.org/10.1182/blood-2019-129876

Published: 2019

Journal Articles

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

Blood (2019) 133 (14): 1548–1559.

https://doi.org/10.1182/blood-2018-10-881961

Published: 2019

Includes: Supplemental data

Journal Articles

FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years

James M. Foran, MD, Zhuoxin Sun, PhD, Elisabeth Paietta, PhD, Janis Racevskis, PhD, David F. Claxton, MD, Hillard M Lazarus, MD, Daniel A. Arber, MD, Jacob M. Rowe, MD, John Godwin, MD, Yanming Zhang, MD, Martin S. Tallman, MD, Mark R. Litzow, MD, Keith W. Pratz, MD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 3995.

https://doi.org/10.1182/blood-2018-99-117838

Published: 2018

NARROW

Single Cell Transcriptomic Analysis of B-Cell Acute Lymphoblastic Leukemia (B-ALL) Reveals Correlation between Leukemia Cell State, Genetic Alterations and Clinical Outcome

The Impact of Age and Genomics on Drug Sensitivity in 1,076 Children and Adults with B-Cell Acute Lymphoblastic Leukemia

STAG2/LMO2 Gamma-Delta (γδ) T-ALL: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Dynamic Recruitment of Inhibitory Complexes Controls Oncogenic Signaling in B-Cell Malignancies

A Pro-Inflammatory Gene Signature Characterizes a Better Risk Aged AML Patient Group in ECOG-ACRIN Cancer Research Group's Clinical Trial E3999

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

DNA Polymerase Theta Protects Leukemia Cells from Metabolic-Induced DNA Damage

Epigenetic Fine Mapping and Functional Dissection of Inherited Non-Coding Variation Impacting the Pharmacogenomics of Acute Lymphoblastic Leukemia Treatment

PAX5 Epigenetically Orchestrates CD58 Transcription and Modulates Blinatumomab Response in Acute Lymphoblastic Leukemia

Chromatin Accessibility Landscapes of B-Cell Acute Lymphoblastic Leukemia Identify Extensive Epigenomic Reprogramming and Heterogeneity Among Subtypes

Characteristics and Prognostic Effects of DNMT3A Co-Mutations

A Phosphatase Membrane-Shuttle Enables Feedback Control of B-Cell Signaling

Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152

Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study

Molecular classification improves risk assessment in adult BCR-ABL1– negative B-ALL

Early Assessment of Treatment Response in Acute Myeloid Leukemia Using FLT PET/CT Imaging: A Trial of the ECOG-ACRIN Cancer Research Group (EAI141)

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only